

CORCEPT THERAPEUTICS INCORPORATED
CONDENSED BALANCE SHEETS
(in thousands)

	<u>September 30,</u> 2011	<u>December 31,</u> 2010
	(Unaudited)	(Note)
ASSETS:		
Current assets:		
Cash and cash equivalents	\$ 45,909	\$ 24,578
Other current assets	<u>427</u>	<u>418</u>
Total current assets	46,336	24,996
Other assets	<u>43</u>	<u>108</u>
Total assets	<u>\$ 46,379</u>	<u>\$ 25,104</u>
LIABILITIES AND STOCKHOLDERS' EQUITY:		
Current liabilities:		
Accounts payable	\$ 1,066	\$ 817
Other current liabilities	<u>1,647</u>	<u>3,043</u>
Total current liabilities	2,713	3,860
Total stockholders' equity	<u>43,666</u>	<u>21,244</u>
Total liabilities and stockholders' equity	<u>\$ 46,379</u>	<u>\$ 25,104</u>

Note: Derived from audited financial statements at that date.

CORCEPT THERAPEUTICS INCORPORATED
CONDENSED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)

(Unaudited)

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,	
	<u>2011</u>	<u>2010</u>	<u>2011</u>	<u>2010</u>
Operating expenses:				
Research and development*	\$ 3,228	\$ 5,224	\$ 14,355	\$ 14,286
General and administrative*	<u>3,209</u>	<u>1,881</u>	<u>8,049</u>	<u>5,327</u>
Total operating expenses	<u>6,437</u>	<u>7,105</u>	<u>22,404</u>	<u>19,613</u>
Loss from operations	(6,437)	(7,105)	(22,404)	(19,613)
Interest and other income, net	3	4	3	758
Other expense	<u>(1)</u>	<u>(3)</u>	<u>(17)</u>	<u>(18)</u>
Net loss	<u>\$ (6,435)</u>	<u>\$ (7,104)</u>	<u>\$ (22,418)</u>	<u>\$ (18,873)</u>
Basic and diluted net loss per share	<u>\$ (0.08)</u>	<u>\$ (0.10)</u>	<u>\$ (0.27)</u>	<u>\$ (0.28)</u>
Shares used in computing basic and diluted net loss per share	<u>84,188</u>	<u>72,045</u>	<u>83,000</u>	<u>66,982</u>
*Includes non-cash stock-based compensation of the following:				
Research and development	\$ 110	\$ 45	\$ 432	\$ 170
General and administrative	<u>844</u>	<u>500</u>	<u>1,971</u>	<u>1,361</u>
Total non-cash stock-based compensation	<u>\$ 954</u>	<u>\$ 545</u>	<u>\$ 2,403</u>	<u>\$ 1,531</u>